Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term TRK-820 (nalfurafine) for intractable pruritus in chronic liver disease
jRCT2080221262Phase 3
- Sponsor
- Toray Industries
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nalfurafine in chronic liver disease (CLD) and pruritus, sponsored by Toray Industries.
02
Drugs
nalfurafine
03
Conditions
chronic liver disease (CLD)pruritus
Beyond the preview
Go deeper on jRCT2080221262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221262.